嘉应制药
(002198)
| 流通市值：40.30亿 | | | 总市值：40.30亿 |
| 流通股本：5.08亿 | | | 总股本：5.08亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 259,604,624.04 | 180,201,567.26 | 94,415,395.08 | 533,233,202.29 |
| 营业收入 | 259,604,624.04 | 180,201,567.26 | 94,415,395.08 | 533,233,202.29 |
| 二、营业总成本 | 256,532,928.46 | 175,374,905.21 | 89,135,396.31 | 495,412,870.71 |
| 营业成本 | 110,541,535.59 | 78,865,625.27 | 43,435,475.92 | 185,513,061.1 |
| 税金及附加 | 4,793,445.6 | 3,259,586.97 | 1,699,351.77 | 9,066,936.33 |
| 销售费用 | 103,992,488.16 | 70,416,333.35 | 33,029,036.77 | 244,765,452.69 |
| 管理费用 | 32,779,996.48 | 19,523,355.14 | 9,383,083.48 | 48,059,350.66 |
| 研发费用 | 5,583,739.76 | 4,151,551.22 | 2,031,024.37 | 10,098,497.62 |
| 财务费用 | -1,158,277.13 | -841,546.74 | -442,576 | -2,090,427.69 |
| 其中:利息费用 | - | 212.54 | 86.07 | 445.34 |
| 其中:利息收入 | 1,182,665.06 | 861,844.43 | 459,049.54 | 2,124,029.58 |
| 加:公允价值变动收益 | 127,440.66 | 162,947.51 | - | 529,953 |
| 加:投资收益 | 590,765.52 | 988,875.28 | -928,149.33 | 578,374.4 |
| 资产处置收益 | 1,606,951.4 | 1,602,244.41 | 1,602,244.41 | 135,256.74 |
| 资产减值损失(新) | -854,420.55 | -1,227,007.76 | - | -824,242.64 |
| 信用减值损失(新) | -353,872.07 | -301,414.86 | - | 695,257.84 |
| 其他收益 | 525,226.87 | 376,527.84 | 300,922.29 | 1,580,555.6 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 4,713,787.41 | 6,428,834.47 | 6,255,016.14 | 40,515,486.52 |
| 加:营业外收入 | 271,919.19 | 271,920.76 | 22,116.53 | 225,935.27 |
| 减:营业外支出 | 178,372.42 | 107,650 | 26,600 | 1,367,753.94 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 4,807,334.18 | 6,593,105.23 | 6,250,532.67 | 39,373,667.85 |
| 减:所得税费用 | 1,933,988.23 | 925,365.31 | 1,068,344.83 | 5,053,433.21 |
| 六、净利润 | 2,873,345.95 | 5,667,739.92 | 5,182,187.84 | 34,320,234.64 |
| 持续经营净利润 | 2,873,345.95 | 5,667,739.92 | 5,182,187.84 | 34,320,234.64 |
| 归属于母公司股东的净利润 | 2,873,345.95 | 5,667,739.92 | 5,182,187.84 | 34,320,234.64 |
| (一)基本每股收益 | 0.01 | 0.01 | 0.01 | 0.07 |
| (二)稀释每股收益 | 0.01 | 0.01 | 0.01 | 0.07 |
| 九、综合收益总额 | 2,873,345.95 | 5,667,739.92 | 5,182,187.84 | 34,320,234.64 |
| 归属于母公司股东的综合收益总额 | 2,873,345.95 | 5,667,739.92 | 5,182,187.84 | 34,320,234.64 |
| 公告日期 | 2024-10-31 | 2024-08-29 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |